TrialRMD open2023

Secukinumab improves physical function and quality of life and inhibits structural damage in patients with PsA with sustained remission or low disease activity: results from the 2-year phase 3 FUTURE 5 study.

Laura C Coates et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.